New data publishing 11/11 in Cell Stem Cell provides strong support for the first-in-human universal gene therapy trial for ...

Find out what is driving the slowdown in gene therapy investment, as the sector continues to struggle with widespread layoffs ...

Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a ...

Despite the availability of three approved therapies targeting the SMA protein, individuals like [Liza] are still at risk of losing function over time, given the inherent progressive nature of SMA ...

After the speakers' presentation, there will be a question-and-answer session. [Operator instructions] Again as a reminder, today's conference is being recorded. At this time, I would like to turn the ...

Cash runway is not expected to get Intellia to meaningful data readouts for their Phase III trials. See why NTLA stock is a ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At ...

Q3 2024 Earnings Call Transcript November 1, 2024Rapid Micro Biosystems, Inc. misses on earnings expectations.

The team also asks for access to the patient's medical history in order to characterise the nature of the disease and its progression ... happening between the antigens and antibodies. Tracking gene ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...